David S. Shames

发表

Integrative Analysis of Two Cell Lines Derived from a Non-Small-Lung Cancer Patient - A Panomics Approach

Fan Zhang, Robert Gentleman, Oleg Mayba, 2014, Pacific Symposium on Biocomputing.

sIR: siRNA Information Resource, a web-based tool for siRNA sequence design and analysis and an open access siRNA database

Michael A. White, John D. Minna, David S. Shames, 2007, BMC Bioinformatics.

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

Robert Gentleman, Florian Gnad, John D. Minna, 2012, Nature Genetics.

Quantitative comparison of DNA methylation assays for biomarker development and clinical applications

Kimberly Walter, David S. Shames, Peter W. Laird, 2016, Nature Biotechnology.

Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

David S. Shames, Matthew D. Hellmann, Garrett M. Frampton, 2016 .

Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells

Calum MacAulay, John D. Minna, David S. Shames, 2009, PloS one.

Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations

John D. Minna, David S. Shames, Yang Xie, 2013, Molecular Cancer Research.

A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non− small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).

David S. Shames, David E. Gerber, Jeffrey R. Infante, 2013 .

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Jacob Silterra, David S. Shames, Craig A. Cummings, 2018, Nature Medicine.